Skip to main content
Emcure Pharmaceuticals Limited logo

Emcure Pharmaceuticals Limited — Investor Relations & Filings

Ticker · EMCURE ISIN · INE168P01015 LEI · 335800WYB6OIBY9EOZ42 BSE.NS Manufacturing
Open in API
Filings indexed 201 across all filing types
Latest filing 2024-11-29 Board/Management Inform…
Country IN India
Listing BSE.NS EMCURE

About Emcure Pharmaceuticals Limited

https://www.emcure.com

Emcure Pharmaceuticals Limited is a research-driven global pharmaceutical organization engaged in the development, manufacturing, and marketing of a broad range of differentiated pharmaceutical products. The company maintains a diverse portfolio across several key therapeutic areas, including gynaecology, cardiovascular, oncology, anti-infectives, and HIV/AIDS. With a strong emphasis on research and development, Emcure operates multiple state-of-the-art manufacturing facilities and R&D centers globally. Its business model focuses on complex generics and innovative formulations, serving healthcare needs in over 70 countries. The company is recognized for its vertically integrated operations and commitment to high-quality standards, catering to both regulated and emerging markets worldwide.

Recent filings

Filing Released Lang Actions
Resignation
Board/Management Information Classification · 100% confidence The document is a formal communication addressed to stock exchanges regarding the resignation of a senior management personnel, Mr. Aravamuthan Balaji, President - IT & Digital. It references compliance with SEBI Listing Regulations, specifically Regulation 30, which mandates disclosure of material events including changes in senior management. The content includes the resignation letter and details about the resignation date and reason. There are no financial statements, earnings data, or report attachments. The document is an announcement of a management change rather than a full report or financial filing. Therefore, it fits the category of Board/Management Information (MANG). The document length is 4600 characters, which is consistent with a detailed announcement but not a full report.
2024-11-29 English
Resignation
Board/Management Information Classification · 95% confidence The document is a formal notification addressed to stock exchanges about the resignation of a Non-Executive and Non-Independent Director of Emcure Pharmaceuticals Limited. It references Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which pertains to disclosure of events or information by listed entities. The content includes the resignation letter and details about the director's cessation of office. There are no financial statements, earnings data, or report publications. The document clearly relates to a change in the company's board of directors. Therefore, it fits the category of Board/Management Information (MANG). The document length is 4417 characters, which is sufficient for a detailed announcement but not a full report. Hence, the classification is MANG with high confidence.
2024-11-23 English
Copy of Newspaper Publication
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges regarding the publication of a newspaper advertisement about the Notice of Postal Ballot. It references compliance with SEBI regulations and confirms the dispatch of the Notice of Postal Ballot dated November 7, 2024. The document is short (2327 characters) and primarily serves as an announcement of the publication of the notice rather than the notice itself or the voting results. There is no detailed voting result, financial data, or management discussion. Therefore, it is best classified as a Regulatory Filing (RNS) because it is a regulatory disclosure announcement that does not fit other specific categories like Declaration of Voting Results or Proxy Solicitation.
2024-11-23 English
Shareholders meeting
Regulatory Filings Classification · 95% confidence The document is an official communication from Emcure Pharmaceuticals Limited addressed to stock exchanges regarding a Notice of Postal Ballot. It references Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and details the sending of the Notice of Postal Ballot dated November 7, 2024, for shareholder approval on amendments to the Employee Stock Option Scheme. The document also mentions the e-voting process and timelines, and states that the results will be declared later. The document itself is a notice about the postal ballot and voting process, not the ballot results or the actual report of voting outcomes. It is relatively short (4171 characters) and serves as an announcement of the postal ballot notice and related procedural information. Therefore, it fits best under the category of Declaration of Voting Results & Voting Rights Announcements (DVA) as it pertains to voting rights and shareholder approval processes, although it is prior to the results. However, since it is a notice of postal ballot and voting process, it is more accurately classified as a Regulatory Filing (RNS) because it is an announcement under SEBI regulations about the voting process, not the actual voting results or a report. The document does not contain voting results or detailed shareholder meeting materials, so DVA is not appropriate. Hence, Regulatory Filings (RNS) is the best fit.
2024-11-22 English
Allotment of Securities
Share Issue/Capital Change Classification · 100% confidence The document is an official communication addressed to stock exchanges regarding the allotment of equity shares pursuant to the exercise of Employee Stock Options (ESOPs). It references compliance with SEBI Listing Regulations and details the increase in issued and paid-up share capital due to the allotment. The content is focused on informing about a capital change event (allotment of shares) rather than presenting financial results, management discussion, or other report types. The document length is short (2403 characters) and is a notification rather than a full report. Therefore, it fits the category of Share Issue/Capital Change (SHA).
2024-11-22 English
Analysts/Institutional Investor Meet/Con. Call Updates
Call Transcript Classification · 100% confidence The document is a detailed transcript of an earnings conference call for Q2 FY25 of Emcure Pharmaceuticals Limited. It includes management commentary on financial results, business updates, and a Q&A session. The text references the release of quarterly financial results and provides substantive financial data such as revenue, EBITDA, PAT, margins, and business segment performance. The presence of a full transcript of the earnings call, including management discussion and Q&A, clearly identifies this as a Call Transcript (CT). It is not merely an announcement or summary but a full transcript of the event.
2024-11-13 English

Browse filings by year

3 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.